research

Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle

Authors
    Publication date
    Publisher
    BioMed Central
    Doi

      Abstract

      Abstract is not available.

        Similar works

        Full text

        thumbnail-image

        Available Versions

        Springer - Publisher Connector

        redirect
        Last time updated on 30/04/2017